Ryan C Lynch

17PUBLICATIONS
100CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)PharmacogenomicsTumour immunologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Jul 17, 2026
Incidence and clinical impact of absolute lymphocyte count-only progression in chronic lymphocytic leukemia.

|Mar 19, 2026
Real-world evidence for pembrolizumab gemcitabine vinorelbine and liposomal doxorubicin in classical Hodgkin lymphoma.

Grace Baek, Gaurav Varma, Samuel Yamshon

|Dec 29, 2025
Brentuximab vedotin and nivolumab in combination with chemotherapy for nonbulky, early-stage classical Hodgkin lymphoma.

Jeremy S Abramson, David J Straus, Nancy L Bartlett

|Dec 09, 2025
Pharma steps back from Hodgkin lymphoma: now what?

Ryan C Lynch, Ajay K Gopal

|Oct 27, 2025
Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell Lymphoma.

Edward R Scheffer Cliff, Guido D Pelaez, Fei Wan

|Oct 10, 2025
Long-term follow-up of dose-dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second-line treatment of relapsed/refractory classical Hodgkin lymphoma.

Ryan C Lynch, Ryan D Cassaday, Stephen D Smith

Pageof 3

Frequent Collaborators

8 joint publications

Mazyar Shadman

7 joint publications

Stephen D Smith

7 joint publications

Chaitra Ujjani

5 joint publications

Edus H Warren